RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. on April 12, 2019, covering events occurring on April 12 and April 15, 2019. The company is incorporated in Nevada and operates from New York, NY.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure amendments.
Material Changes
- Stock Option Plan Amendment: On April 15, 2019, the Company executed an amendment to its 2014 Stock Option and Equity Incentive Plan. This amendment increases the number of shares of common stock authorized for issuance under the plan to 10,111,718 shares.
- Charter Amendment: On April 12, 2019, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State. This action increases the total number of authorized shares of common stock from 100,000,000 to 200,000,000 shares.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operations, or specific risk factors. Both the Plan Amendment and the Charter Amendment were previously approved by stockholders at the 2018 annual meeting held on February 27, 2019. Full text of the amendments will be filed as exhibits to the Form 10-Q for the quarter ended March 31, 2019.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (200,000,000) on potential future dilution.
- Confirm the specific terms of the 2014 Stock Option and Equity Incentive Plan amendment in the upcoming Form 10-Q exhibit.
- Review the February 28, 2019 Form 8-K (Item 5.07) for details on the stockholder approval process for these amendments.